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Here, we tested two hypothesis; (1) a long-term delivery of bone
morphogenetic protein-2 (BMP-2) would enhance ectopic bone
formation compared to a short-term delivery at an equivalent
dose, (2) human cord blood mesenchymal stem cells (hCBMSCs)
that are not osteogenically differentiated prior to implantation
would regenerate bone extensively in vivo once exogenous BMP-2
was delivered to the implantation site. Heparin-conjugated poly(L-
lactide-co-glycolide) (PLGA) nanospheres (HCPNs) suspended in
ﬁbrin gel (group 1) were developed for a long-term delivery of
BMP-2. Fibrin gel containing normal PLGA nanospheres (group 2)
was used for short-term delivery of BMP-2. The in vitro release of
BMP-2 from group 1 was sustained for four weeks with no initial
burst release. In contrast, 83% of BMP-2 loaded in group 2 was
released only for the ﬁrst three days. Group 1 induced bone for-
mation to a much greater extent than did group 2 upon implantation
into rat hind limb muscle. On the other hand, undifferentiated
hCBMSCs on BMP-2-loaded scaffolds induce far more extensive
bone formation in mouse calvarial defects than either undifferen-
tiated hCBMSCs or osteogenically differentiated hCBMSCs. These
results show that long-term delivery of BMP-2 enhances in vivo
osteogenic efﬁcacy of the protein compared to short-term delivery
at an equivalent dose, and the BMP-2 delivery could prove in-
valuable for in vivo regeneration of bone from undifferentiated
hCBMSCs.
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Tissue engineering (TE) has emerged in the last decade of the 20th
century as an alternative approach to circumvent the existent
limitations in the current therapies for organ failure or replace-
ment. The EU HIPPOCRATES project joined academic and in-
dustrial partners to develop novel products and concepts that can
be used for bone, cartilage or osteochondral TE strategies. Several
issues were addressed including i) the choice and study of adequate
human cell cultures, (ii) the development of culture technology
with which human tissues can be grown ex vivo in three dimen-
sional biodegradable matrices, (iii) the development of a mate-
rial technology with which polymeric matrices can be produced,
being suitable for cell culture (proliferation, differentiation), (iv)
to assess the in-vivo functionality and clinical relevance of
the tissue engineering strategies. In this context, we proposed the
use of a series of natural-based biomaterials, namely polysac-
charides (e.g. starch, chitin derivatives, alginate, carrageenan,
gellan gum) compounded, or not, with synthetic polymers and
ceramics, including calcium phosphates obtained from mineralized
red algae. A series of processing techniques and surface modiﬁ-
cations were used to produce scaffolds with a wide range of po-
rosity and porous architecture and controlled surface features.
Hydrogels, including thermo-responsive injectable systems, were
produced as biodegradable supports and vehicles for cells and
growth factors. Complementary studies were performed to use the
same kind of materials in drug release systems; such information
could be integrated in tissue engineering strategies where growth
factors or differentiation agents could be delivered in a controlled
way to progenitor cells.
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There is great need to design functional bioactive substitute
materials capable of surviving harsh and diverse conditions
within the body. Hydroxyapatite (HA) is a well established sub-
stitute material for orthopaedic and dental applications. The lit-
erature suggests that porous HA displays better osteoconductivity.
A recent study by Roy et al [1] concluded that meso-porous
ceramic material signiﬁcantly improved the percentage of new
bone formation when compared to non-porous ceramic material.
The purpose of our research was to develop a bioceramic from
algal origins suitable for bone tissue application. Corallina ofﬁ-
cinalis was selected as the source material for two main rea-
sons (1) it has a high surface area owing to its highly porous
interconnective morphology and (2) it is a magnesium rich
calcite.
Low-temperature hydrothermal synthesis achieved the conver-
sion of Corallina to HA in a simple and cost-effective manner [2].
The resultant material contained a calcium phosphate apatite phase
of approximately 90%, with a pore size of <10 microns and spe-
ciﬁc surface area of 124.1m2/g. This morphology provides an
additional mechanism for cellular activity and offers the potential
for use as a drug delivery system. Furthermore, cell studies show
that the material can support cell growth, thus indicating its bio-
compatibility. These physiochemical properties make this material
an ideal candidate for tissue engineering applications.
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